Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma

Phase 2

Completed

Conditions: Ovarian Mucinous Cystadenocarcinoma
Ovarian Serous Cystadenocarcinoma
Ovarian Undifferentiated Adenocarcinoma
Ovarian Endometrioid Adenocarcinoma
Brenner Tumor
Ovarian Clear Cell Cystadenocarcinoma
Fallopian Tube Cancer
Stage III Ovarian Epithelial Cancer
Stage IV Ovarian Epithelial Cancer

Interventions: Drug: paclitaxel
Drug: carboplatin
Drug: erlotinib

First Posted Date: 2003-05-07

Last Posted Date: 2015-12-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 56

Registration Number: NCT00059787

Locations: 🇺🇸
Montefiore Medical Center, Bronx, New York, United States

Gemcitabine, Carboplatin or Paclitaxel Plus Radiation Therapy in Treating Patients With Stage IIIA or IIIB Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer

Interventions: Drug: gemcitabine hydrochloride
Drug: carboplatin
Drug: paclitaxel
Radiation: radiation therapy

First Posted Date: 2003-05-07

Last Posted Date: 2015-11-17

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 35

Registration Number: NCT00016315

Locations: 🇺🇸
CCOP - Bay Area Tumor Institute, Oakland, California, United States
🇺🇸
Wendt Regional Cancer Center of Finley Hospital, Dubuque, Iowa, United States
🇺🇸
Delaware County Memorial Hospital, Drexel Hill, Pennsylvania, United States

and more 16 locations

Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: paclitaxel
Procedure: conventional surgery
Radiation: radiation therapy

First Posted Date: 2003-05-07

Last Posted Date: 2022-02-03

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 19

Registration Number: NCT00043108

Locations: 🇺🇸
Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States

PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer

Phase 1

Completed

Conditions: Primary Peritoneal Cancer
Fallopian Tube Cancer
Ovarian Cancer

Interventions: Drug: PS-341 (Bortezomib)
Drug: Carboplatin

First Posted Date: 2003-04-30

Last Posted Date: 2012-08-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 21

Registration Number: NCT00059618

Locations: 🇺🇸
University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States

Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors

Phase 1

Completed

Conditions: Cancer

Interventions: Biological: recombinant human thrombopoietin
Drug: carboplatin
Drug: etoposide
Drug: ifosfamide
Biological: G-CSF

First Posted Date: 2003-04-18

Last Posted Date: 2014-07-24

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 16

Registration Number: NCT00003597

Locations: 🇺🇸
Long Beach Memorial Medical Center, Long Beach, California, United States
🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇺🇸
Herbert Irving Comprehensive Cancer Center, New York, New York, United States

and more 21 locations

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1

Conditions: Ovarian Cancer
Primary Peritoneal Cavity Cancer
Fallopian Tube Cancer

First Posted Date: 2003-04-18

Last Posted Date: 2014-01-06

Lead Sponsor: Herbert Irving Comprehensive Cancer Center

Target Recruit Count: 30

Registration Number: NCT00003064

Locations: 🇺🇸
Herbert Irving Comprehensive Cancer Center, New York, New York, United States

Combination Chemotherapy Followed by Radiation Therapy in Patients With Small Cell Lung Cancer

Phase 3

Completed

Conditions: Lung Cancer

First Posted Date: 2003-04-16

Last Posted Date: 2013-12-19

Lead Sponsor: Medical Research Council

Target Recruit Count: 400

Registration Number: NCT00002822

Locations: 🇬🇧
Medical Research Council Clinical Trials Unit, London, England, United Kingdom

Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Recurrent Acute Leukemia

Phase 1

Completed

Conditions: Leukemia
Neutropenia

First Posted Date: 2003-04-11

Last Posted Date: 2011-08-03

Lead Sponsor: Mayo Clinic

Registration Number: NCT00002693

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia

Phase 2

Terminated

Conditions: Childhood Diffuse Large Cell Lymphoma
Childhood Immunoblastic Large Cell Lymphoma
Recurrent Childhood Large Cell Lymphoma
B-cell Childhood Acute Lymphoblastic Leukemia
L3 Childhood Acute Lymphoblastic Leukemia
Recurrent Childhood Acute Lymphoblastic Leukemia
Childhood Burkitt Lymphoma
Recurrent Childhood Lymphoblastic Lymphoma
Recurrent Childhood Small Noncleaved Cell Lymphoma

Interventions: Drug: ifosfamide
Drug: etoposide
Biological: rituximab
Drug: carboplatin
Biological: filgrastim
Drug: methotrexate
Drug: cytarabine
Other: laboratory biomarker analysis

First Posted Date: 2003-04-09

Last Posted Date: 2013-10-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 82

Registration Number: NCT00058461

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: paclitaxel
Radiation: three-dimensional conformal radiation therapy

First Posted Date: 2003-04-09

Last Posted Date: 2017-12-22

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 63

Registration Number: NCT00023673

Locations: 🇺🇸
Mobile Infirmary Medical Center, Mobile, Alabama, United States
🇺🇸
Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States
🇺🇸
CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States

and more 38 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy